Vertex
Vertex presents promising new data from cystic fibrosis trials
June 9, 2025Medical Communications, Research and Development European Cystic Fibrosis Conference, Rare Diseases, Vertex, clinical trial, cystic fibrosis
Vertex Pharmaceuticals has presented new data showing the clinical and quality-of-life benefits of its cystic fibrosis (CF) therapies, particularly Alyftrek …
Vertex scores EU approval for cystic fibrosis drug Kalydeco in R117H+ children and adolescents
June 10, 2020Research and Development, Sales and Marketing Kalydeco, Vertex, cystic fibrosis, ivacaftor, pharma
Vertex has revealed that it has secured a new approval from the European Commission for its therapy Kalydeco (ivacaftor) in …
Vertex’s Kalydeco seizes EU CHMP recommendation for Kalydeco in R117H+ cystic fibrosis
May 1, 2020Medical Communications, Sales and Marketing Europe, Kalydeco, Vertex, cystic fibrosis
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has given its recommendation for the approval …
Data revealed on novel CRISPR/Cas9 gene-editing therapy for first two severe haemoglobinopathy patients
November 19, 2019Manufacturing and Production, Research and Development Vertex, crispr, pharma
Vertex and CRISPR Therapeutics have unveiled the first interim Phase 1/2 data demonstrating the safety and efficacy of the investigational …
Vertex’s cystic fibrosis portfolio to be made available across Northern Ireland and Wales
November 13, 2019Research and Development, Sales and Marketing Kalydeco, NHS, Orkambi, Symkevi, Vertex, pharma
After drawn out negotiations and much discontent among cystic fibrosis (CF) patients and their advocates, Vertex has announced that a …
FDA approves Vertex’s Trikafta in new indication, now potentially covering 90% of cystic fibrosis patients
October 23, 2019Research and Development, Sales and Marketing FDA, Trikafta, Vertex, cystic fibrosis, pharma
The FDA has granted marketing authorisation to Vertex’s Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF), it …
Vertex cystic fibrosis drugs become available in Scotland after NHS rejection
September 12, 2019Sales and Marketing SMC, Vertex, cystic fibrosis
Two potentially life-changing cystic fibrosis drugs are to become available for a potential pool of 400 patients in Scotland just …
Scotland turns down Vertex’s Orkambi
August 13, 2019Manufacturing and Production Orkambi, SMC, Scotland, Vertex, cystic fibrosis, pharma
The Scottish Medicines Consortium (SMC) has turned down Vertex’ cystic fibrosis drug Orkambi on the grounds that it is not …
FDA expands Vertex’s cystic fibrosis drug Symdeko in paediatric patients
June 24, 2019Sales and Marketing FDA, Symdeko, Vertex, cystic fibrosis, pharma
Vertex has announced that the FDA has chosen to expand the existing authorisation on its cystic fibrosis (CF) therapy Symdeko …
Top Ten most popular articles on Pharmafile.com this week!
June 14, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, GSK, J&J, JJ, Otsuka, Pfizer, Purdue, Sanofi, Vertex, pharma
Pfizer supressed research showing their arthritis drug Enbrel reduced the risk of Alzheimer’s. This was the big revelation this week! …
MPs discuss breaking Vertex’s IP rights to bring Orkambi to UK
June 11, 2019Research and Development Orkambi, Vertex, access, house of commons, pharma, pricing
MPs yesterday discussed circumventing Vertex’s patent on cystic fibrosis medicine Orkambi (Lumacaftor/ivacaftor) as a means of breaking the deadlock and …
Parents of children with cystic fibrosis start Orkambi buyers club
June 5, 2019Research and Development NHS, Orkambi, Vertex, cystic fibrosis
Parents of children with cystic fibrosis have started an Orkambi buyers’ club to import generic versions of Vertex’s drug from …
The price of access: Can the NHS afford Orkambi?
April 29, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Drug pricing, NHS, NICE, Orkambi, UK, Vertex, access, cystic fibrosis, feature, pharma, pricing
The impasse over access to Vertex’s Orkambi for cystic fibrosis patients in England and Wales has revealed the cracks in …
Vertex destroyed nearly 8,000 packs of Orkambi in 2018
March 28, 2019Medical Communications, Sales and Marketing Briatin, Orkambi, UK, Vertex, cystic fibrosis
Vertex destroyed nearly 8,000 packs of the $272,000 a year cystic fibrosis drug Orkambi in 2018, the company said in …
Vertex doubles Q4 profits, angering cystic fibrosis drug advocates in UK
February 11, 2019Sales and Marketing Orkambi, Vertex, cystic fibrosis, pharma
Despite ongoing controversy surrounding the currently stalled negotiations between Vertex and the NHS to make its cystic fibrosis (CF) drug …
